Navigation Links
BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute
Date:5/20/2013

ROCKVILLE, Md. and BALTIMORE, May 20, 2013 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced its selection of Ram Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) for BHI at the National Institutes of Health's (NIH) National Heart, Lung and Blood Institute (NHLBI). Dr. Aiyar will help advance fundamental research discoveries to new therapeutics, diagnostics and devices that can be used clinically and commercially.

"We're pleased to add Dr. Aiyar to our roster of Entrepreneurs-in-Residence," said Rich Bendis, BHI President and CEO. "He is now our third EIR – joining Todd Chappell , who is EIR at NIH, and Ken Malone , our EIR working with the University of Maryland Ventures. The growth of this program will be a benefit to BHI and our partner organizations for years to come, and will result in transitioning more early-stage biomedical technologies to commercial potential."

As the newest EIR, Dr. Aiyar will rely on his extensive experience providing guidance to life science companies in the therapeutic, diagnostic and medical device space and evaluating commercial, scientific, regulatory, and development feasibility. He will work closely with NHLBI scientific, medical, and technology transfer staff members to identify, evaluate, and support the advancement of early-stage biomedical technologies within the NHLBI mission to practical application and public benefit. 

"I am excited to use my scientific, investment and operational background to help with commercialization of assets and technologies from within the NHLBI with the support of BHI," said Dr. Aiyar. "Working with phenomenal people at BHI – with the backing of many of the most talented and reputable health care advisors in the Maryland Area – is a unique and exciting opportunity. I look forward to working with both the BHI and NHLBI teams."

"This partnership between NHLBI and BHI will help us accelerate our efforts in the commercialization space," said Jodi Black , Ph.D., Deputy Director, Division of Extramural Research Activities, NHLBI. "We're excited about the opportunity to have Dr. Aiyar assisting our efforts to transition laboratory discoveries to practical application and public benefit."

About Ram Aiyar
Dr. Aiyar brings over five years of experience in pharmaceutical research and development and two years of healthcare investment experience to his role as CCO at FlowMetric, Inc. Dr. Aiyar is also an investment professional at Sofinnova Partners, a healthcare venture capital firm based in Paris. There, Dr. Aiyar is responsible for identifying, building and supporting biotech and medtech start-ups. Prior to Sofinnova, Dr. Aiyar worked at Johnson & Johnson (J&J) in the oncology and immunology space. Most recently, Dr. Aiyar was focused on developing and identifying stratified medicine solutions for pulmonary and autoimmune diseases as part of the immunology biomarkers team. At J&J, Dr. Aiyar also contributed in identification and development of several novel large molecular compounds in oncology and immunology. Dr. Aiyar was a recipient of the Philip B. Hofmann award for "Outstanding Achievement in the field of Research and Development," the most prestigious award for a scientist at J&J.

Dr. Aiyar's doctoral research used a combination of experimental and statistical methods to differentiate the mechanism of action of three different erythropoietin agonists. Dr. Aiyar also completed an investment banking internship at J.P. Morgan (London) in the Healthcare Advisory group. His doctoral research combined with experience at J&J has led to the filing of several international patents and over 20 peer reviewed articles.

Dr. Aiyar received an M.B.A. from INSEAD, a Ph.D. and M.S. in Electrical and Computer Engineering from Drexel University and a B.E. from Mumbai University.

About NHLBI
Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at http://www.nhlbi.nih.gov.

About the National Institutes of Health (NIH)
NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery Into Health

About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.


'/>"/>
SOURCE BioHealth Innovation, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioHealth Innovation, Inc. Launches Program to Help Life Science Companies Navigate Federal Funding Application Process
2. BioHealth Innovation, Inc. President & CEO Richard Bendis to Present at SXSW 2013 & 2013 BIO International Convention
3. BioHealth Innovation, Inc. Forms Commercial Relevance Advisory Board to Help Advance Market-Relevant Innovations in Central Maryland
4. Two Baltimore Business Leaders are BioHealth Innovation, Inc.s Newest Board Members
5. BioHealth Innovation, Inc. Caps Next Phase Of Development With Move To New Headquarters And Addition Of Staff
6. Economic Alliance of Greater Baltimore Inks Business Partnership with BioHealth Innovation to Bring Health and Life Sciences Research to Market
7. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
8. Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
9. ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development
10. Regenesis Biomedical Names Scott Brooks Chief Executive Officer
11. Tunnell Consulting Names John S. Ross as Principal, Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its national ... Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based ... selected for membership in ARCS Alumni Hall of Fame . ASTER Labs ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is ... and 8th June 2018 in San Francisco, CA. The Summit brings together current and ... distinguished CEOs, board directors and government officials from around the world to address key ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):